html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

PapersPMID:35913424

Effect of 1% malic acid spray on diabetes mellitus-induced xerostomia: A randomized clinical trial.

Oral diseases2024The record ↗

malic acid

raisesUnstimulated whole salivary flow rate

What moved

1 findingHow to read these marks →

Increases unstimulated whole salivary flow rate
very limited
“A sialogogue spray containing 1% malic acid increased the unstimulated salivary flow rate in patients with type 2 diabetes mellitus suffering from xerostomia.”
Study
RCT
Duration
14 days
Dose studied
1% malic acid topical sialogogue spray, on demand for 2 weeks
Population
Patients with type 2 diabetes mellitus and xerostomia, randomised to 1% malic acid spray or placebo spray, assessed at 2 weeks follow-up

Study record

Design: randomised controlled trial
Species: human
Population: Patients with type 2 diabetes mellitus suffering from xerostomia
Participants: 52
Comparator: placebo
Duration: 14 days
Endpoints measured: 4
Declined: this platform holds no node for the endpoint